Use of dolutegravir-based first-line antiretroviral therapy (ART) in response to rising levels of pretreatment HIV drug resistance (PDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) may be limited, given safety concerns for birth defects in women of child-bearing potential. Pooled data from 11 nationally representative surveys show that NNRTI PDR in women is nearly twice that in men, exceeding 10% in 8 of 11 countries monitored, suggesting the urgent need for a non-NNRTI-based ART regimen in this population.
aDepartment of HIV and Global Hepatitis Programme, World Health Organization, Geneva, Switzerland
bTufts University School of Medicine, Boston, USA
cU1058 lab, INSERM, University of Montpellier, Montpellier, France
dPan American Health Organization, Washington DC, USA
eWorld Health Organization, Regional Office for Africa, Brazzaville, Congo
fWorld Health Organization, Regional Office for the Western Pacific, Manila, Philippines
gAIDS & TB Unit, Ministry of Health and Child Care, Harare
hDirectorate of Special Programes for HIV, TB, and Malaria, Ministry of Health and Social Services, Windhoek, Namibia
iCentre de Recherche sur les Maladies Emergentes et Reemergentes (CREMER), Virology laboratory IMPM-IRD, IMPM, Yaoundé, Cameroon and Institut de Recherche pour le Développement (IRD) UMI 233, INSERM U1175, Université de Montpellier, Montpellier, France
jHealth Operational Research, Ministry of Public Heath, Cameroon
kNational AIDS Control Commitee, Yaounde, Cameroon
lUganda Virus Research Institute and MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda.
Correspondence to Silvia Bertagnolio, MD, Department of HIV and Global Hepatitis Programme, World Health Organization, Avenue Appia, Geneva, Switzerland. Tel: +41 79 7288078; e-mail: firstname.lastname@example.org
Received 18 August, 2018
Accepted 21 September, 2018